Weight Loss with Medication vs. Natural Approach: The Pros and Cons Nobody Tells You

I’m going to be straight with you from the start.

This is not another article that will tell you that medication is bad and that nature cures everything. Nor the opposite. The reality — which the science of 2025 and 2026 shows us — is more complex and much more interesting than either of those simple narratives.

The question most people ask is "medication or a natural approach?". The right question is different: what works best for whom, under what circumstances, and for how long?

Let’s break this down with real data.

The Efficacy Gap: The Numbers No One Places Side-by-Side

Before any opinion, the facts.

The landmark clinical trials — published in the New England Journal of Medicine, JAMA, and The Lancet — show consistent results for the main GLP-1 medications currently available in Portugal:

• Semaglutide (Wegovy), 2.4 mg dose: average weight loss of -14.9% of body weight over 68 weeks in the STEP-1 trial
• Semaglutide, new 7.2 mg dose (STEP UP): average loss of -20.7% over 72 weeks
• Tirzepatide (Mounjaro), 15 mg (SURMOUNT-1): average loss of -20.9% over 72 weeks
• Head-to-head comparison (SURMOUNT-5): tirzepatide -20.2% vs. semaglutide -13.7% over 72 weeks

And the natural approach? The largest lifestyle intervention clinical trial ever conducted — the Look AHEAD trial, with intensive and supervised diet and exercise intervention — showed an average loss of -8.5% at year 1.

The difference is real: in a clinical trial context, medications produce 2 to 4 times more weight loss than structured and supervised lifestyle interventions.

Point to the medications, here.

So Why Do Half of the People Stop?

Here is where the first major complication arises.

The Danish national registry followed the first 77,310 adults without diabetes who started semaglutide for weight loss. The result: 52% stopped within 1 year. Of those, 18% stopped within the first 3 months.

In the US, data from 125,474 adults (JAMA Network Open, 2025) show that 64.8% of users without diabetes abandoned treatment within 12 months.

Why? The most common reasons are:

• Gastrointestinal effects — nausea, vomiting, diarrhea — which affected 70.8% of users of the highest dose in the STEP UP trial
• Cost — in Portugal, Wegovy costs €198.53 to €245 per month; Mounjaro costs €244 to €430 per month depending on the dose. Without SNS (National Health Service) reimbursement for weight loss, this amounts to €2,400 to over €5,000 per year
• Weight regain upon stopping — which leads to the next point

What Happens When You Stop: The Rebound Effect in Real Numbers

This is the part that most people are unaware of — and which completely changes how one thinks about these medications.

Two independent studies from 2026, published in the most respected medical journals, reached aligned conclusions:

eClinicalMedicine 2026 (Budini et al.) — meta-regression of 48 studies with 3,236 participants:

• At 1 year after stopping: 60% of lost weight is regained
• The mathematical model projects a plateau of 75.3% regain — meaning only about 25% of the initial benefit is maintained long-term

BMJ 2026 (West et al., University of Oxford) — meta-analysis of 37 studies with 9,341 adults:

• Average overall regain rate: +0.4 kg per month
• Specifically for semaglutide and tirzepatide: +0.8 kg per month after stopping
• Projection: return to baseline weight within 1.5 to 2 years after stopping
• Aggravating factor: weight regain after stopping medication is +0.3 kg/month faster than after finishing an intensive lifestyle program

The SURMOUNT-4 trial confirms this with direct tirzepatide data: 82% of those who stopped regained at least 25% of the lost weight within 1 year.

Why does this happen? When the exogenous agonist stops, the body is not "cured" — it was suppressed. Ghrelin (the hunger hormone) returns, energy expenditure drops, and those who did not develop different eating habits during treatment experience the rapid return of hunger often informally called "food noise."

The Muscle Mass Problem

Here is something that rarely appears in conversations about these medications — and which has real long-term implications.

During treatment with GLP-1, 20 to 40% of the weight lost corresponds to lean mass, not fat. When weight is regained after stopping, the body preferentially recovers fat, not muscle.

The result is a body composition potentially worse than before starting treatment — more fat, less muscle, in a phenomenon that medicine calls sarcopenic obesity.

Current science clearly recommends: 1.2 to 1.6 g/kg/day of protein and supervised resistance training during treatment, not after. It is not optional — it is what the evidence says to mitigate this loss.

So What Does the Natural Approach Offer — Long-Term?

Let’s return to Look AHEAD: at year 8, the average maintained weight loss was -4.7%. Less than medications in the short term — but maintained without financial cost and without gastrointestinal side effects.

The major limitation of the natural approach is not the mechanism — it is adherence. The body develops physiological adaptations that make maintaining lost weight difficult: it increases hunger and reduces resting energy expenditure. This is not a lack of willpower — it is biology.

But there is a fundamental difference between stopping a diet and stopping a medication: those who develop habits during a lifestyle intervention have behavioral tools that persist. Those who only suppressed hunger with a medication did not develop those tools.

The BMJ 2026 data is revealing here: the rebound after stopping medication is 0.3 kg/month faster than after finishing a lifestyle intervention. This difference precisely reflects the absence of behavioral skills acquired during pharmacological treatment.

For Whom Does Medication Make the Most Sense?

Science is clear about the profile that benefits most:

• BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with associated complications
• Type 2 diabetes — improves both weight and glycemic control (and is covered by the SNS)
• Established cardiovascular disease — the SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide
• Moderate to severe sleep apnea — tirzepatide has specific approval for this indication
• Metabolic dysfunction-associated steatohepatitis (MASLD) — efficacy demonstrated in specific trials

For those without these clinical conditions, the benefits are real but harder to justify against the cost — both financial and in terms of side effects.

The Third Way: Combining Both Approaches

The most recent evidence points to something that the 2025 guidelines from major European medical societies already incorporate: medications work best when combined with lifestyle changes, and those who develop habits during treatment maintain much more of the benefit after stopping.

The ATTAIN-MAINTAIN trial showed that transitioning from an injectable to an oral agonist (Foundayo) can preserve lost weight — those who transitioned from injectable to oral semaglutide regained only 0.9 kg in 52 weeks, compared to 9.0 kg in the group that stopped completely.

And resistance training integrated during treatment showed it preserves body composition and supports weight maintenance after stopping — something medication alone cannot achieve.

The practical conclusion: if medications are an option, use them as a lever to develop habits, not as a substitute for them.

Comparative Table: GLP-1 Medications vs. Natural Approach

What This Means in Practice

If you are considering medication: the short-term efficacy data is real and impressive. But planning from the start must include what happens next — resistance training, adequate protein, and the development of habits that persist.

If you prefer the natural approach: results are slower and biology will work against you at certain times. But what you develop is yours — it doesn't disappear when you stop a medication.

If you are using medication and eventually want to stop: science says the transition must be planned, gradual, and accompanied by a solid foundation of habits. Stopping abruptly without that foundation is the recipe for the rebound that the 2025-2026 data describes.

For those who prefer a non-prescription approach, there are natural ingredients with research supporting metabolism and appetite regulation — although with effects much more gradual than any GLP-1 medication. Kyoslim, manufactured in the European Union with DGAV authorization, combines five natural ingredients — EGCG, Guarana, L-Carnitine, Raspberry Extract, and Niacin — as complementary support for those on a natural and sustainable path. It is not a substitute for prescribed medication — it is a different tool for a different stage of the journey.

FAQ

If medications are more effective, why don't you recommend them to everyone?

Because short-term efficacy is not the same as long-term results. With abandonment rates of 52-65% at 1 year, costs of €2,400 to €5,000 annually without coverage, and 60-75% of weight regained after stopping, medications make more sense for specific clinical profiles — not as a first line for the entire population.

Will I regain all the weight if I stop the medication?

Data shows that the majority regain a significant portion — 60% of what was lost at 1 year, with an estimated plateau at 75%. But there is real heterogeneity: 56% of users in a real-world study of 188,722 people either maintained their weight or continued to lose after stopping, generally those who had developed habits during treatment.

Can the natural approach yield results similar to medication?

In terms of magnitude, no — the efficacy gap is 2 to 4 times. But in terms of long-term maintained results, especially for those who sustain habits, the distance is smaller than short-term clinical trials suggest.

In Portugal, when will there be coverage for weight loss?

INFARMED is evaluating a 30-40% co-payment model for patients with severe obesity and comorbidities. The estimate is that the framework will be finalized between late 2026 and early 2027.

Can I combine the natural approach with a healthy lifestyle without using medication?

Yes — and that is exactly what science recommends as a starting point for most people. Medications are adjuvants, not substitutes. Dietary habits and exercise are the foundation recommended by all major European medical societies, regardless of any medication.

Important Disclaimer: This article is for educational purposes only. GLP-1 medications (Ozempic, Wegovy, Mounjaro) are prescription drugs that should only be used under medical supervision. Never start, stop, or change medication without consulting your doctor. The natural supplements mentioned are not intended to diagnose, treat, cure, or prevent any disease and do not replace prescribed medication.

Important Health Information

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Results may vary by individual. Consult your healthcare professional before starting any new supplementation or medication regimen, especially if you have existing health conditions or take medication.

The statements in this article have not been evaluated by regulatory authorities. Supplements are not intended to diagnose, treat, cure, or prevent any disease.